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1. Background to the study 
Chapter 1 | 
11 
in vitro
2. The aryl hydrocarbon receptor, roles, and ligands  
2.1. Generalities and roles 
 
Figure 1. Simplified scheme of the activation of the AhR pathway by AhR ligands. Ligands entering 
the cell (1) bind to the Ah-receptor; (2) activating the latter and initiating the recruitment of the 
AhR Nuclear Translocator (ARNT) and translocation of the ligand-AhR/ARNT complex from the 
cytoplasm to the nucleus (3). The complex then binds to specific dioxin responsive elements (DREs), 
DNA regions present in the promoter regions of AhR target genes and increases their expression (4). 
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’
2.2. Ligands of the AhR 
dioxins’ 
Chapter 1 | 
13 
. 
3. Health effects of toxic AhR ligands 
in vivo in vitro
“dioxin like” toxicity. 
in-vivo adverse effects, the term “dioxin like” toxicity does not strictly apply
3.1. Dioxins 
1
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3.2. Polycyclic aromatic hydrocarbons 
Chapter 1 | 
15 
4. Hazard and risk assessment 
4.1. Dioxins 
1
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4.2. Polycyclic aromatic hydrocarbons 
in vitro
4.3. Mycotoxins 
here is limited data available regarding the toxicity of aflatoxins’ 
Chapter 1 | 
17 
5. Bioassays for the analysis of AhR-mediated activity; principle and applications 
5.1. Principle 
 
Figure 2.  AhR-mediated mechanism of luciferase gene expression in a reporter gene assay. See text 
for further explanation. 
5.2. Analysis of AhR-active mixtures 
1
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5.3. Hazard assessment of individual chemicals 
in vitro
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19 
in vitro 






Chapter 5 in vitro
Chapter 6
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7. Involvement in the Horizon 2020 ITN ProtectED project 























induced alterations in sexual and functional development : 
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Bhattacharya, S., O’Shaughnessy, P.J., 2008. Maternal Smoking during Pregnancy 
–










































































Chapter  2 –  
 
Induction of AhR transactivation by PBDD/Fs and 
PCDD/Fs using a novel human-relevant, high-
throughput DRhuman CALUX reporter gene assay 
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2. Material and methods 
2.1. Chemicals 
2.2. Cell lines and culturing 
essential amino acids (NEAA), respectively, and streptomycin (10μg/mL) plus penicillin 
CALUX cells were cultured in α
streptomycin (10μg/mL) plus penicil
(10μg/mL) plus penicillin (10U/mL) antibiotics.




2.3. Transient transfections 
mix was prepared, and the cells were transfected. The transfection mix consisted of 1μg 
exposure. The exposure medium was then prepared and 800μL of assa
shaker for approximatively 10 minutes. Finally, 30μL of the lysate was transferred to 
2.4. Stable transfections 
method according to the manufacturer’s instructions (Invitrogen, CA USA). This method 
the transfection and was equal to 600 μg/mL.
2.5. DRhuman and DR CALUX analyses 
Chapter 2 |
37 
2.6. CALUX high-throughput analyses  
2.7. Data analysis  




%𝐶𝐶𝐶𝐶 =  100 ∗ (%𝑆𝑆𝑆𝑆 𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀)⁄









1 − ((3 × 𝑆𝑆𝑆𝑆𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 + 3 × 𝑆𝑆𝑆𝑆ℎ𝑖𝑖𝑖𝑖ℎ𝑒𝑒𝑒𝑒𝑒𝑒 [𝑇𝑇𝑇𝑇𝐷𝐷𝐷𝐷] ) (𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 − 𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀ℎ𝑖𝑖𝑖𝑖ℎ𝑒𝑒𝑒𝑒𝑒𝑒[𝑇𝑇𝑇𝑇𝐷𝐷𝐷𝐷])) ⁄
2.8. Relative potency calculations 
 in vitro 
𝑅𝑅𝐸𝐸𝑅𝑅𝑥𝑥 = 𝐸𝐸𝐶𝐶502,3,7,8−𝑇𝑇𝑇𝑇𝐷𝐷𝐷𝐷 𝐸𝐸𝐶𝐶50𝑥𝑥⁄
Chapter 2 |
39 
3. Results and discussion 
3.1. Development and characterization of a novel DRhuman CALUX cell line 




Figure 1. Responsiveness of human U2OS, HT29, HEK293, C2BBe1 and HepG2 cell lines transiently 
transfected with an AhR-responsive reporter plasmid to 3E-10M and 10E-9M of 2,3,7,8-TCDD after 




Figure 2. 2,3,7,8-TCDD dose-response curves of the DRhuman CALUX at three different culture 
passages as compared to the typical dose-response curve obtained in the rat H4IIe based DR CALUX 
bioassay (mean ± SD). 
 
Table 1.  Performance characteristics of the DRhuman CALUX bioassay in the 96-well plate format and 
high-throughput screening (HTS) 384-well format (mean ± SD). 





3.2.  Establishment of an automated high throughput assay format 














Table 2. PC5 (5% 2,3,7,8-TCDD activity equivalent), PC50 (50% 2,3,7,8-TCDD activity 
equivalent), EC50 and maximal efficacy (%TCDDmax) values for the PCDD/Fs and PBDD/Fs 
determined in DRhuman and DR CALUX cells. Values are expressed in molar (M) and are a 











































































































Table 3. Relative potency values of several PCDD/Fs and PBDD/F congeners calculated based on 
5% of 2,3,7,8-TCDD activity (PC5) in the DR CALUX bioassay and congener-specific ratio 
REPPCDD/F/REPPBDD/F that illustrate congener-specific differences. 
PCDD/Fs REP PC5 (M) Ratio REP PC5 (M) PBDD/Fs 
2,3,7,8-TCDD 2 2,3,7,8-TBDD 
1,2,3,7,8-PeCDD 1 1,2,3,7,8-PeBDD 
1,2,3,4,6,7,8-HpCDD 10 1,2,3,4,6,7,8-HpBDD 
OCDD 11 OBDD 
2,3,7,8-TCDF 0.5 2,3,7,8-TBDF 
2,3,4,7,8-PeCDF 1 2,3,4,7,8-PeBDF 
1,2,3,7,8-PeCDF 5 1,2,3,7,8-PeBDF 
1,2,3,4,7,8-HxCDF 8 1,2,3,4,7,8-HxBDF 
1,2,3,4,6,7,8-HpCDF 11 1,2,3,4,6,7,8-HpBDF 
OCDF 18 OBDF 
Table 4. Relative potency values of several PCDD/Fs and PBDD/F congeners calculated based on 
5% of 2,3,7,8-TCDD activity (PC5) in the DRhuman CALUX bioassay and congener-specific ratio 
REPPCDD/F/REPPBDD/F that illustrate congener-specific differences. 
PCDD/Fs REP PC5 (M) Ratio REP PC5 (M) PBDD/Fs 
2,3,7,8-TCDD 2 2,3,7,8-TBDD 
1,2,3,7,8-PeCDD 1 1,2,3,7,8-PeBDD 
1,2,3,4,6,7,8-HpCDD 69 1,2,3,4,6,7,8-HpBDD 
OCDD - OBDD 
2,3,7,8-TCDF 0.2 2,3,7,8-TBDF 
2,3,4,7,8-PeCDF 1 2,3,4,7,8-PeBDF 
1,2,3,7,8-PeCDF 4 1,2,3,7,8-PeBDF 
1,2,3,4,7,8-HxCDF 4 1,2,3,4,7,8-HxBDF 
1,2,3,4,6,7,8-HpCDF 3 1,2,3,4,6,7,8-HpBDF 









Table 5. DRhuman CALUX REPEC50 values and WHO-TEF values for PCDD/Fs and PBDD/Fs and ratio 
REPEC50/WHO-TEF illustrating the differences between the two values. 
Congener 
 DRhuman CALUX WHO TEF 
(2005,2013)1  
 Ratio 
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Detection of high PBDD/Fs levels and dioxin-like 
activity in toys using a combination of GC-HRMS, 
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Abstract 
present in plastic constituents of toys could pose a threat to children’s health. PB
levels present in contaminated plastic constituents from children’s toys. Finally
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57 
1. Introduction    
1996; Vugt‐Lussenburg et al., 2013). The quantification of the total toxic potency of 
3
| Chapter 3 
58 
contaminants in children’s toys made of recycled plastic.
children’s toys using a combination of GC
Chapter 3 | 
59 
2. Material and methods 
2.1. Chemicals  
2.2. Samples and sample preparation 
3
| Chapter 3 
60 
2.3. GC-HRMS analysis for PBDD/Fs 
10 “Determination of the mass concentration of PCDD/Fs, PBDD/Fs 
like PCBs in solid matter samples”. For 1,2,3,6,7,8
inner diameter, and 0.1 μm film thickness). The MS was operated in Selected Ion 
congener’s 
2.4. Cell lines and culturing 
in α
Chapter 3 | 
61 
2.5. CALUX analyses of pure compounds and extracts from toys and consumer 
products 
2.6. Data analysis and quality control of CALUX analysis 
2.6.1. Analysis of individual congeners 
(Y = Bottom + (Top − Bottom)/(1 + 10^((LogEC50 − X) × HillSlope)
2.6.2. Determination of relative potency values 
3
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62 
2.6.3. Sample extracts analysis and BEQ determination 
3. Results & Discussion 
3.1. Determination of relative potencies of individual PBDD/F and PCDD/F 
congeners in rat- and human-cell based CALUX bioassays   
six PBDD/Fs congeners that were either representative of congener’s prevalence in the 
Chapter 3 | 
63 
 
Figure 1. Typical dose-response curve for several chlorinated and brominated dibenzo-p-dioxins 
and dibenzofuran in DR CALUX (A) and DRhuman CALUX (B) (n ≥ 2). Values represent the mean ± SD.  
3
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Table 1. Lowest effective concentration (LOEC), EC10%, EC50 and Relative Potency (REP) 
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3.2. Determination of PBDD/Fs levels (by GC-HRMS), and total dioxin-like activities 
in toy samples using DRs CALUX bioassays 
relative to their contribution to the total ΣPBDD/Fs TEQ levels was similar between the 
3
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66 
Vugt‐Lussenburg et al., 
ditive, antagonism, synergism…) 
Chapter 3 | 
67 
Table 2. Concentrations of PBDD/F (pg/g) congeners as measured by GC-HRMS in plastic 
materials from toys; total sample concentration (pg/g) and WHO-2005 based TEQ values 
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Figure 2. PBDFs congeners pattern in six toys measured by HR-GCMS presented in percentage of 
contribution to the total concentration of PBDFs (pg/g) (A) and percentage of contribution to the 
total TEQ (B).  
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Table 3. Total equivalent activity (TEQ) values measured in analyzed toys and consumer goods 
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3.3. Hazard assessment of plastic toys contaminant uptake by children through 
mouthing behaviour 
Chapter 3 | 
71 
children’s dioxin body bur
ment that PBDD/Fs can  “contribute significantly to the total 
amount of TEQ“ (van den Berg et al., 2013), and should
3
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72 
Figure 3. Estimation of the additional daily intake in young children of PBDD/Fs in plastic 
toys from mouthing behaviour. Estimation of the pg TEQ/kg body weight/day is based on 
the ingestion of 8 mg of the black plastic parts of sampled toys and A) HR-GCMS congener 
concentrations converted to apparent TEQ values, using TEF values for analogous 
chlorinated congeners of dioxins and furans; B) using DR CALUX and C) DRhuman BEQ values. 
Weight-for-age values are based on WHO child growth standards. 
Chapter 3 | 
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4. Conclusion 
PBDD/Fs in children’s toys and observation that these compounds are being potent 
  
3
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Assessment of the effect of maternal smoking on 
placental and foetal hepatic AhR activity using a 
CALUX reporter gene assay with improved 
sensitivity, the DRhp CALUX 
ǂ ǂ,














(O’Shaughnessy et al., 2011)
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2. Material and Methods 
2.1. Samples 
Chapter 4 | 
85 
2.2. Chemicals 
2.3. Cell-culture media 
2.4. Cell lines and cell culture 
using the Lipofectamine 2000 method according to the manufacturer’s instructions 
–
2.5. CALUX analysis of pure compounds and samples 
4
| Chapter 4 
86 
2.6. Preparation of reference material and B[a]P-fortified reference material 
2.7. Sample extraction 
– –
– –
2.8. Determination of CALUX bioanalytical-equivalents, quality control 
Chapter 4 | 
87 
2.9. Data analysis and performance determination 
𝑌𝑌 = 𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 +  (𝑇𝑇𝐵𝐵𝑇𝑇 − 𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵)/(1 + 10^((𝐿𝐿𝐵𝐵𝐿𝐿𝐿𝐿𝐿𝐿50 − 𝑋𝑋) ∗ 𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐵𝐵𝑇𝑇𝐻𝐻
%𝐿𝐿𝐶𝐶 =  100 ∗ (%𝐻𝐻𝑆𝑆 𝑀𝑀𝐻𝐻𝑀𝑀𝑀𝑀)⁄









𝐿𝐿𝐿𝐿𝑆𝑆 = 𝑀𝑀𝐻𝐻𝑀𝑀𝑀𝑀𝑏𝑏𝑏𝑏𝑏𝑏𝑛𝑛𝑏𝑏 + (3 × 𝐻𝐻𝑆𝑆𝑏𝑏𝑏𝑏𝑏𝑏𝑛𝑛𝑏𝑏)
4
| Chapter 4 
88 
3. Results and discussion 
3.1. Optimization of the DRhp CALUX bioassay for the determination of B[a]P-
equivalent activity 
Table 1. Comparison of the DRhp and DR CALUX bioassays based on the EC50 for 2,3,7,8-TCDD, limit 
of detection, luciferase activity and fold induction
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Figure 1. Dose-response of DRhp CALUX cells exposed to Benzo[a]pyrene for different incubation 
periods ranging from 1h to 24h (mean ± SD). 
4
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3.2. DRhp CALUX analysis of placenta and foetal liver samples 
Chapter 4 | 
91 
Table 2. Summary of bioanalytical B[a]P-equivalent activity in placenta samples measured with 
DRhp CALUX 
 Control (n=13)      Smoke-exposed (n=16) 
 Mean BEQ 
ng B[a]P-eq./g  SD Range 
 Mean BEQ 








Table 3. Summary of bioanalytical B[a]P-equivalent activity in foetal liver samples measured with 
DRhp CALUX.  
Figure 2: B[a]P-equivalent activity per individual placenta sample from smokers (n = 16) 
and non-smokers (n = 13) measured with the DRhp CALUX and expressed as ng B[a]P-
equivalent activity per gram of tissue. 
 Control (n=13)      Smoke-exposed (n=16)  
 Mean BEQ 
ng B[a]P-eq./g  SD Range 
 Mean BEQ 
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4. Conclusion  
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Supplementary data.  B[a]P-equivalent bioactivity in foetal liver derived from chemically 






Male foetal liver 
(Fowler et al. 2008) 
Female foetal liver 
(Fowler et al. 2014) 





Pieterse et al. 
(2013) 
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Evaluation of the B[a]P equivalent activity in male foetal liver (Fowler et al., 2008): 
Congener 
 Control 








































Total mol B[a]P-equivalent/g  
Total ng B[a]P-equivalent/g
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Evaluation of the B[a]P equivalent activity in female foetal liver (Fowler et al., 2014) 
Congener 
 Control 








































Total mol B[a]P-equivalent/g  
Total ng B[a]P-equivalent/g
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Versicolorin A enhances the genotoxicity of 
Aflatoxin B1 in human liver cells by inducing the 
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Abstract 




Aspergillus flavus A. parasiticus
Aspergillus
AFB1 in certain food commodities (Abdallah et al., 2017; Abia et al., 2013; Janić Hajna
s (Gauthier et al., 2020; Jakšić et al., 2012; Theumer et al., 2018). 
articularly in organs relevant to AFB1’s toxicity such as the liver.
in vivo
5
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2. Material and methods 
2.1. Chemicals  
2.2. Synthesis and purification of versicolorin A 
Aspergillus parasiticus A. parasiticus
Chapter 5 | 
105 
 
2.3. Cell lines and culturing 
maintained in α
(10μg/mL) plus penicillin (10U/mL) antibiotics. The assay medium used for exposure to 
5
| Chapter 5 
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2.4. Cytotoxicity determination 
(Le et al., 2018)
assay was performed according to the manufacturer’s instructions. Briefly, sub
2.5. Gene expression analysis  
  
Table 1. primer sequences for SYBR Green quantitative PCR analysis. 
 
2.6. CALUX analyses 
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compounds were considered “positive” in the DR
positive control and tested compounds were considered “positive” when the response of 
2.7. γH2AX in cell-western  
γ
γH2AX (Clone 20E3, Cell signalling) primary antibody. 
CorScienceTec, Les Ulis, France). γH2AX and RedDot2 signals from treated 
fluorescence. γH2A
5
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2.8. Data handling  
≤ ≤ ≤
3. Results and discussion 




Figure 1. Effects of versicolorin A (VerA) and aflatoxin B1 (AFB1) on cell viability in HepG2 cells 
measured using the CellTiter-Glo® assay (mean ± SD)
Chapter 5 | 
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Figure 2. Individual effects of aflatoxin B1 (AFB1) and versicolorin A (VerA) on (A) H2AX 
phosphorylation in HepG2 cells measured using the yH2Ax-ICW bioassay, on (B) p53 
transcriptional activity in the HepG2-p53 CALUX bioassay and on (C) on the p53-Ser15 
phosphorylation in wild-type HepG2 cells exposed to 1μM of each toxin, or vehicle control 
(DMSO) for 24h (mean ± SD). 
5
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3.3. Comparative Induction of AhR and expression of CYP450 enzymes by 
versicolorin A and aflatoxin B1 
μ μ
Figure 3. Effects of versicolorin A (VerA) and aflatoxin B1 (AFB1) on the AhR-mediated luciferase 
induction in HepG2 DRhuman CALUX reporter cells after 4 h of incubation (mean ± SD). 
Chapter 5 | 
113 
 
Figure 4. Effects of 1µM versicolorin A (VerA) and 1µM of aflatoxin B1 (AFB1) on the mRNA 
transcription induction of CYP1A1/2 and CYP3A4 in HepG2 cells (mean ± SD). *: p-value ≤ 0.05; **: 
≤ 0.01; ***: ≤ 0.001. 
5
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3.4. Versicolorin A enhances the genotoxicity of aflatoxin B1  
γ




Figure 5. Effects of versicolorin A (VerA) and aflatoxin B1 (AFB1) and mixtures of AFB1 + 1uM of 
VerA on cell viability in HepG2 cells measured using the CellTiter-Glo® assay (mean ± SD). *: p-value 
≤ 0,05.
llah et al., 2017; Janić Hajnal et al., 2020; Kovalsky et al., 2016)
5
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Figure 6. Combined effects of aflatoxin B1 (AFB1) and 1uM of versicolorin A (VerA) on (A) 
H2AX phosphorylation in HepG2 cells measured using the yH2Ax-ICW bioassay and (B) p53 
transcriptional activity in HepG2-p53 CALUX bioassay and (C) p53-Ser15 phosphorylation 
in wild-type HepG2 cells compared to their individual effects (mean ± SD). **: p-value ≤ 0.01; 
***: ≤ 0.001. 
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Supplementary Figure 1. Chemical structure of aflatoxin B1 (AFB1) and versicolorin A (VerA). In 
the AFB1 structure, the green circle highlights the known double bond target of CYP450s enzymes. 
In the VerA structure, the green circle indicates the putative reactive double bond, and the dashed 
blue circle highlights the anthraquinone and its β-hydroxy group. 
 
Supplementary Figure 2. Individual effects of aflatoxin B1 (AFB1) and versicolorin A (VerA) on 
p53 transcriptional activity in the U2OS-p53 CALUX bioassay (mean ± SD). 




Supplementary Figure 3. Effects of versicolorin A (VerA) and aflatoxin B1 (AFB1) on the AhR-
mediated luciferase induction in (A) DRhuman CALUX cells after 24 hours of incubation and in (B) DR 
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General discussion & future outlook 
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1. Improvements of AhR-based bioassays with a focus on human exposure and 
impact assessment 
1.1. The DRhuman CALUX bioassay 
which seems to only be the case for the HG2L7.5c1 that is used in EPA’s TOX21 screening 
Chapter 6 | 
127 
 
Table 1. Comparison of the DRhuman CALUX with existing HepG2-based AhR reporter gene assays. 
relevance concerning dioxins’ distribution in the human
in vitro
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1.2. DRhigh-performance CALUX (DRhp)  
to improve the bioassay’s limit of detection and luciferase reporter responsiveness, 
Chapter 6 | 
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Table 2: Comparison of H4IIE-based AhR responsive CALUX bioassays. 










2. Demonstration of the applicability the novel AhR-based CALUX bioassays in 
human-oriented hazard assessment of chemicals and mixtures thereof 
2.1. Performances of the DRhuman CALUX and DRhp CALUX 
in vitro
"Guidance on good in vitro method practices"
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2.3. Assessment of complex (AhR-active) mixtures 
ers’ 
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2.4. Possible human health impact of observed effects using the newly developed 
AhR-based bioassays. 
present in children’s toys made from recycled plastic) an
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, via zogenaamde “mout ng behavior” van kinderen
















de composés capable d’interagir avec le AhR dans l’environnement peut être associée à 




l’activité médiée par le AhR a été de d’obtenir la meilleure
d’étudier 
l’effet de (mélange de) composés sur l’AhR dans un contexte cellulaire humain dans le but 
d’évaluer les risques pour la santé humaine. Par conséquent, la première étape dans cette 
chapitre 2








Ensuite, les potentiels d’induction des dioxines obtenus avec le DR
chapitre 3
Montrant ainsi qu’il est possible 
d’utiliser le DR CALUX pour l’analyse de mixtures complexes et la quantification 
d’analogues de dioxines. ’
autres contaminants capables d’activer l’
degré plus élevé de pertinence pour l’
d’activité médiée par le AhR






CALUX s’avère plus 
essais CALUX quantifiant l’activation du AhR, en particulier 
et échantillons de foie de fœtus humain afin d'étudier l'effet du tab
l'activité AhR placentaire et hépatique du fœtus
Il n’y avait pas 
de différence significative entre les foies des fœtus de mères non
AhR, avec de possibles implications pour le développement des fœtus exposés, tels que la 
d’activer le AhR dans des échantillons complexes. En revanche, pou
l’Homme. Cel
chapitre 5
d'étudier le rôle possible de la voie de signalisation de l’AhR dans la génotoxicité des 
in vitro
CALUX et des études d’expression 
d’activer le AhR de manière dose
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